Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial - David Erritzøe; Tommaso Barba; Kyle T. Greenway; Roberta Murphy; Jonny Martell; Bruna Giribaldi; Christopher Timmermann; Ashleigh Murphy-Beiner; Michelle Baker Jones; David Nutt; Brandon Weiss; Robin Carhart-Harris (EClinicalMedicine, 2024)

Acute psilocybin and ketanserin effects on cerebral blood flow: 5-HT2AR neuromodulation in healthy humans - Larsen K; Lindberg U; Ozenne B; McCulloch DE; Armand S; Madsen MK; Johansen A; Stenbæk DS; Knudsen GM; Fisher PM. (medRxiv, 2024)

AEs reported after use of psychedelics such as psilocybin (Reactions Weekly, 2024)

Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates the gabapentin-mediated analgesia - Askey T; Allen-Ross D; Lasrado R; Gilmour G; Hunt S; Tamagnini F; Ahmed M; Stephens G; Maiarú M. (Research Square, 2024)

Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study - James Rucker; Matthew Butler; Sadie Hambleton; Catherine Bird; Mathieu Seynaeve; Sanjay Cheema; Kete Campbell-Coker; Carolina Maggio; Fiona Dunbar; Giorgio Lambru; Manjit Matharu (Headache The Journal of Head and Face Pain, 2024)

Quantitative LC-QToF-MS Analysis of Mycochemicals in Amanita muscaria, Psilocybe spp. (Agaricomycetes), and Consumer Products - Kumar Katragunta; Bharathi Avula; Amar G. Chittiboyina; Hemant Lata; Ikhlas A Khan (International journal of medicinal mushrooms, 2024)

Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus - University Hospital; Ghent (ClinicalTrials.gov, 2024)

CCNP Innovations in Neuropsychopharmacology Award: The psychopharmacology of psychedelics: where the brain meets spirituality. - Gobbi G. (2024)

Psychedelic research at a crossroads. - Armstrong SB; Davis AK. (2024)

Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents. - Werle I; Bertoglio LJ. (2024)

Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress - Mageean S; Daniel A; Tai S. (Research Square, 2024)

Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials - Danielle B Rodrigues (Journal of Complementary Medicine & Alternative Healthcare, 2024)

Psychedelics as a potential treatment for tobacco use disorder: a systematic review. - Spoelstra SK; Schoevers RA; Venema SD; Knegtering H. (2024)

Exploring the regulatory framework of psychedelics in the US & Europe. - Behera HK; Joga R; Yerram S; Karnati P; Mergu T; Gandhi K; M S; Nathiya D; Singh RP; Srivastava S; Kumar S. (2024)

Less is more? A review of psilocybin microdosing. - Savides IA; Outhoff K. (2024)

New frontiers in the biosynthesis of psychoactive specialized metabolites. - Li G; Facchini PJ. (2024)

Psychedelic mushroom-containing chocolate exposures: Case series. - Gartner HT; Wan HZ; Simmons RE; Sollee DR; Sheikh S. (2024)

An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States - Syed F. Rab; Charles L. Raison; Elliot Marseille (Psychedelics., 2024)

B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations - James Perry; Cara C. Young; Julie Williams (Archives of Clinical Neuropsychology, 2024)

Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases. - Schipper S; Nigam K; Schmid Y; Piechotta V; Ljuslin M; Beaussant Y; Schwarzer G; Boehlke C. (2024)

Psilocybin-Assisted Therapy for Brain Cancer Related Existential Distress: A Case-Report - Jean-François Stephan; Sani Karam (Journal of Palliative Medicine, 2024)

Psilocybin alters brain activity related to sensory and cognitive processing in a time-dependent manner - Nikolic M; Mediano P; Froese T; Reydellet D; Palenicek T. (medRxiv, 2024)

Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review. - Thaoboonruang N; Lohitnavy M; Lohitnavy O. (2024)

Change in occupational burnout measures in emergency medical service workers after a psychedelic experience induced by a single self-administered dose of psilocybin mushrooms - Ana Ferreira; Sharon Martindale; David Luke (Journal of Psychedelic Studies, 2024)

The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies. - Low ZXB; Ng WS; Lim ESY; Goh BH; Kumari Y. (2024)

Usage of Psilocybin to Treat Huntington's Disease: A Research Protocol - Cynthia Duan; Navid Farkhondehpay; Viana Safa; Emma Yuan (Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, 2024)

Psilocybin administered following extinction sessions does not affect subsequent cocaine cue reinstatement in male and female rats and mice - Veronika Pohořalá; Martin Kuchař; Rainer Spanagel; Rick E. Bernardi (Neuroscience, 2024)

Psychoactive substances for the treatment of neuropsychiatric disorders. - Zhen Z; Sun X; Yuan S; Zhang J. (2024)

Psilocybin-induzierte mystische Erfahrungen in subjektiven Berichten: Ein Scoping Review mit qualitativer Inhaltsanalyse. - Anna Graue; Sören Kuitunen-Paul; Henry G. Harder; Lisa Emily Richter (Suchttherapie, 2024)

Einmalig Psilocybin: antidepressive Effekte - Arnim Quante (PSYCH up2date, 2024)

Psilocybin desynchronization persists in the human brain. - Rogers J. (2024)

Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis. - Caspani G; Ruffell SGD; Tsang W; Netzband N; Rohani-Shukla C; Swann JR; Jefferies WA (Pharmacological research, 2024)

Rapidly Trading Down Depression's 3 Pillars to 5HT3-Receptors Through ECT or Psilocybin? - Treviranus GRS. (2024)

Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders. - Loizaga-Velder A; Loizaga Pazzi A. (2024)

Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis. - Smith CL; Sackett N; Stark BC; Dinh V; Romesburg EW; Roll J (Psychedelic medicine (New Rochelle, N.Y.), 2024)

Refractory CRPS pain treated with psilocybin: A case report - David S. Jevotovsky; Harman Chopra; Court Wing; Carlton J. Spotswood; Joel Castellanos (Clinical Case Reports, 2024)

Psilocybin for Treatment of Obsessive Compulsive Disorder - University of Arizona (ClinicalTrials.gov, 2024)

The Birth of the Psychedelic Industry: Capitalizing on the Psychedelic Renaissance - Yoo M; Sakopoulos S. (Authorea Preprints, 2024)

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment]. - Jungwirth J; Bavato F; Quednow BB. (2024)

The role of psilocybin in depressive disorders. - Najib J. (2024)

A Cohort Based Case Series: Learnings from an Iterative Group Therapy Model to Support Psilocybin-Assisted Therapy for Patients with a Terminal Diagnosis - Tsang V. (2024)

Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations - Tsang V; Roney C. (2024)

The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting - Klučková T; Nikolič M; Tylš F; Viktorin V; Vejmola Č; Viktorinová M; Bravermanová A; Androvičová R; Andrashko V; Korčák J; Zach P; Hájková K; et al. (medRxiv, 2024)

Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse - Mark A. Frye; Balwinder Singh; Scott Breitinger; Tyler Oesterle (The Journal of Clinical Psychiatry, 2024)

Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study - Jensen ME; Stenbæk DS; Messell CD; Poulsen ED; Varga TV; Fisher PM; Nielsen MKK; Johansen SS; Volkow ND; Knudsen GM; Fink-Jensen A. (Research Square, 2024)

Classic psychedelics and the treatment for alcoholism. - Lodetti G; de Bitencourt RM; Rico EP. (2024)

Identifying Three Psilocybin Use Patterns by Frequency and Quantity - Bethany A. Gray; Olivia L. Bolts; Deborah J. Fidler; Mark A. Prince (Journal of Studies on Alcohol and Drugs, 2024)

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. - Hsu TW; Tsai CK; Kao YC; Thompson T; Carvalho AF; Yang FC; Tseng PT; Hsu CW; Yu CL; Tu YK; Liang CS. (2024)

Exploring the Therapeutic Potential of Entheogens in Postoperative Cognitive Decline and Psychological Resilience. - Kargbo RB. (2024)

Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine. - Kargbo RB. (2024)

Psilocybin in the Treatment of Mental Disorders - Doğancan Sönmez; Aslı Enzel Koç (DergiPark (Istanbul University), 2024)

A virtual clinical trial of psychedelics to treat patients with disorders of consciousness - Alnagger NL; Cardone P; Martial C; Sanz Perl Y; Mindlin I; Sitt JD; Roseman L; Carhart-Harris R; Nutt D; Mallaroni P; Mason NL; Ramaekers JG; et al. (bioRxiv, 2024)

Comparison between Single-Dose and Two-Dose Psilocybin Administration in the Treatment of Major Depression: A Systematic Review and Meta-Analysis of Current Clinical Trials. - Salvetti G; Saccenti D; Moro AS; Lamanna J; Ferro M. (2024)

Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review. - Kim A; Halton B; Shah A; Seecof OM; Ross S. (2024)

A24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) - Clairvoyant Therapeutics (ClinicalTrials.gov, 2024)

Prevalence and Correlates of Psychedelic Use in Poland: A Study on a Representative Sample of Polish Adults - Holas P; Kaminska J. (Research Square, 2024)

Acute Effects of Psilocybin and Salvinorin-A on Functional Connectivity - Frederick A. Bagdasarian; Hanne D. Hansen; Chi-Hyeon Yoo; Michael S. Placzek; Jacob M. Hooker; Hsiao-Ying Wey (Proceedings on CD-ROM - International Society for Magnetic Resonance in Medicine. Scientific Meeting and Exhibition/Proceedings of the International Society for Magnetic Resonance in Medicine, Scientific Meeting and Exhibition, 2024)

The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis. - Chen MH; Cheng SL; Kao YC; Tseng PT; Hsu CW; Yu CL; Yang FC; Thompson T; Hsu TW; Liang CS. (2024)

Psilocybin for clinical indications: A scoping review. - Madden K; Flood B; Young Shing D; Ade-Conde M; Kashir I; Mark M; MacKillop J; Bhandari M; Adili A. (2024)

Altered states of consciousness in Danish healthy volunteers and recreational users of psilocybin and the possible impact of setting and intention: Danish validation of the five-dimensional altered states of consciousness questionnaire - Oliver Rumle Hovmand; M. Madsen; Patrick M. Fisher; Dea Siggaard Stenbæk (Journal of Psychopharmacology, 2024)

Psilocybin-assisted psychotherapy: Advancements, challenges, and future directions for treating resistant depression - Rodolfo Myronn de Melo Rodrigues (Psychedelics., 2024)

Ayahuasca for the treatment of alcohol use disorder. - Marinho EAV; Serra YA; Oliveira-Lima AJ; Marcourakis T; Berro LF. (2024)

Resurrecting Ancestral Familial Health: A Role for Psilocybin? - Ashley Glowiak (The Family Journal, 2024)

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) - Sheppard Pratt Health System (ClinicalTrials.gov, 2024)

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial - Ottawa Hospital Research Institute (ClinicalTrials.gov, 2024)

Effects of serotonergic psychedelics on synaptogenesis and immediate early genes expression - comparison with ketamine, fluoxetine and lithium - Vella Y; Syrova K; Petruskova A; Koutrouli I; Kutna V; Pala J; Nikolic M; Sichova K; Mazoch V; Jurok R; Kuchar M; Bendova Z; et al. (bioRxiv, 2024)

Letter to editor regarding "Psilocybin-assisted therapy for depression: A systematic review and meta-analysis". - Yang X; Kuang W. (2024)

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms - Brugmann University Hospital (ClinicalTrials.gov, 2024)

Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression - Gustavo Deco; Yonatan Sanz Perl; Samuel Johnson; Niamh Bourke; Robin Carhart-Harris; Morten L. Kringelbach (Nature Mental Health, 2024)

Psilocybin legislation is helping psychedelic drugs make a comeback - a drug researcher explains the challenges they face - Benjamin Y. Fong (2024)

Insights into the efficacy of psilocybin in treating depression and other disorders - Sarah Jane Palmer (British Journal of Neuroscience Nursing, 2024)

Psilocybin-assisted therapy and HIV-related shame - Nicky J. Mehtani; Mallory O. Johnson; Peter S. Hendricks; Jennifer Mitchell; B. Anderson (Scientific Reports, 2024)

Precipitous Increases in Psilocybin Exposure in Youths (AAP Grand Rounds, 2024)

Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study - Véliz-García O; Domic M. (Research Square, 2024)

Psychedelic-assisted psychotherapy: where is the psychotherapy research? - Aday JS; Horton D; Fernandes-Osterhold G; O'Donovan A; Bradley ER; Rosen RC; Woolley JD (Psychopharmacology, 2024)

Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness. - Mograbi DC; Rodrigues R; Bienemann B; Huntley J (Current neurology and neuroscience reports, 2024)

CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS. - Kaiserman A; Vanderjist L; Kornreich C. (2024)

Psilocybin in pharmacotherapy of obsessive-compulsive disorder. - Owe-Larsson M; Kamińska K; Buchalska B; Mirowska-Guzel D; Cudnoch-Jędrzejewska A. (2024)

Psilocybin - A Drug to be Considered for the Treatment of Anxiety and Depression in Cancer Patients - V Suresh; Jitendra Lakhani; R Balaraman (Journal of Natural Remedies, 2024)

We now know what a brain looks like on psilocybin - but what does that tell us? - Michiel van Elk (2024)

How psilocybin affects the brain - Karen O’Leary (Nature Medicine, 2024)

Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users - david J; Berkovich-Ohana A; Dor-Ziderman Y. (PsyArXiv, 2024)

Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users (PsyArXiv, 2024)

Psilocybin for the Treatment of Major Depressive Disorder - Washington University School of Medicine (ClinicalTrials.gov, 2024)

PTSD Treatment: An Inquiry into the Promising Potential of Psilocybin - Ibrahim Lanre Folorunsho; Nkechinyere Mary Harry; Chukwubueze Obiajunwa; Oluwatosin Arubuolawe; Adeniyi Kayode Busari; Chidalu Ibeneme; Gibson Anugwom (Journal of Advances in Medicine and Medical Research, 2024)

Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol - Butler M; Bird C; Maggio C; Durden A; Modlin N; Campbell-Coker K; Edwards M; Pick S; Millman LM; Lowery E; Bhagavan C; Kanaan R; et al. (Wellcome Open Res, 2024)

Molecular insights into the modulation of the 5HT 2A receptor by serotonin, psilocin, and the G protein subunit Gqα - Viohl N; Zanjani AAH; Khandelia H. (bioRxiv, 2024)

Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants - Chiranth Bhagavan; Richard Kanaan; Olivia Carter; Glenn Nielsen; David J. Berlowitz; Sara Issak; Sabine Braat; Sophie Zaloumis; Zachary Attard; Georgina Oliver; Deanne Mayne; David McKernon; et al. (Psychiatric Research and Clinical Practice, 2024)

Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges. - Gomez-Escolar A; Folch-Sanchez D; Stefaniuk J; Swithenbank Z; Nisa A; Braddick F; Idrees Chaudhary N; van der Meer PB; Batalla A. (2024)

Your brain on shrooms - how psilocybin resets neural networks - Max Kozlov (Nature, 2024)

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy - Sara de la Salle; Hannes Kettner; Julien Thibault Lévesque; Nicolas Garel; Shannon Dames; Ryan Patchett-Marble; Soham Rej; Sara G. Gloeckler; David Erritzøe; Robin Carhart-Harris; Kyle T. Greenway (Scientific Reports, 2024)

Psilocybin desynchronizes the human brain - Joshua S. Siegel; Subha Subramanian; Demetrius Perry; Benjamin P. Kay; Evan M. Gordon; Timothy O. Laumann; Travis R. Reneau; Nicholas V. Metcalf; Ravi V. Chacko; Caterina Gratton; Christine Horan; Samuel R. Krimmel; et al. (Nature, 2024)

Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report - André Do; Vanessa Michaud; Jean-François Stephan; Miltiadis Moreau; Élise Benoît; Felix-Antoine Berubé; Antoine Bibaud-De Serres; Alain Taillefer; Philippe Vincent (Frontiers in Psychiatry, 2024)

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study - Anders Fink-Jensen; MD; DMSci (ClinicalTrials.gov, 2024)

Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions - Nogueira M; García-Hernández S; Roberto GS; Marques LZ. (medRxiv, 2024)

Quantitative Natural Language Processing Markers of Psychoactive Drug Effects: A Pre-Registered Systematic Review - Ahuja S; Zaher F; Palaniyappan L. (Research Square, 2024)

Psilocybin for the treatment of Alzheimer's disease. - Zheng S; Ma R; Yang Y; Li G. (2024)

Magic of the Mushrooms: Effects of Psilocybin Decriminalization - Ashutosh Bhave (Journal of Psychoactive Drugs, 2024)

Psychedelics relax predictive processing in the post-acute period by remodeling cortico-cortical feedback circuits - West CL; Imai F; Bastos G; Hornick MA; Rachmany L; Duran A; Nadeem S; Ricci D; Rader Groves AM; Wargo JA; Van Leeuwen N; Sershen H; et al. (bioRxiv, 2024)

Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence - Hussein El Bourji; Aziz Farhat; Zahi Hamdan; Ritvij Satodiya; Rashmi Shukla; Samer El Hayek (Current Psychopharmacologye, 2024)

Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method - Amir Khajavinia; Déborah Michel; Udoka C. Ezeaka; Randy W. Purves; Robert B. Laprairie; Anas El-Aneed (Journal of Chromatography A, 2024)

Mushroom poisoning of Panaeolus subbalteatus from Ningxia, northwest China, with species identification and tryptamine detection. - Yao Y; Zhang YZ; Liang JQ; Liu F; Li ZF; Li HJ; Xu F. (2024)

Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression - Magdalena Kolasa; Agnieszka Nikiforuk; Agata Korlatowicz; Joanna Solich; Agnieszka Potasiewicz; Marta Dziedzicka-Wasylewska; Ryszard Bugno; Adam S. Hogendorf; Andrzej J. Bojarski; Agata Faron-Górecka (Psychopharmacology, 2024)

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression - Joshua M. Poulin; Gregory E. Bigford; Krista L. Lanctôt; Peter Giacobbe; Ayal Schaffer; Mark Sinyor; Jennifer S. Rabin; Mario Masellis; Amit Singnurkar; Christopher B. Pople; Nir Lipsman; Muhammad Ishrat Husain; et al. (Trials, 2024)

Effects of psilocybin on body weight, body composition, and metabolites in male and female mice - Jasmine Shakir; Megan Pedicini; Brianna C Bullock; Penn W Hoen; Lindsey Macias; Jackson Freiman; Mikhail V Pletnikov; Kellie L. Tamashiro; Zachary A. Cordner (Physiology & Behavior, 2024)

Regional Differences of Self-Reported Past-12-month Marijuana, Psilocybin, and Cocaine Use: Results From NDEWS Rapid Street Reporting 2021-2022 - Nae Won; Anna Wang; Joseph J. Palamar; Nicole D. Fitzgerald; MeLisa R. Creamer; Catherine W. Striley; Linda B. Cottler (Drug and Alcohol Dependence, 2024)

Prevalence of Psilocybin and Cannabis Concurrent Use During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study - Denise C. Vidot; Amrit Baral; Bria-Necole Diggs; Sitara M. Weerakoon; Moudou Baquai; Ramessu Iyi; Michelle Weiner; Sarah Messiah (Drug and Alcohol Dependence, 2024)

SPONTANEOUS CHANGES IN CIGARETTE SMOKING FOLLOWING PSILOCYBIN-ASSISTED TREATMENT FOR ALCOHOL USE DISORDER - Broc A. Pagni; Noah D. Gold; Michael P. Bogenschutz (Drug and Alcohol Dependence, 2024)

High Blood Pressure Among Psilocybin and Cannabis Consumers During the COVID-19 Pandemic: An Analysis of the COVID-19 Cannabis Health Study - Denise C. Vidot; Bria-Necole Diggs; Amrit Baral; Michaela E. Larson; Sitara M. Weerakoon; Moudou Baquai; Ramessu Iyi; Michelle Weiner; Marlene Camacho-Rivera; Sarah Messiah (Drug and Alcohol Dependence, 2024)

Acute Psychedelic Effects and Clinical Outcomes are Associated With Therapeutic Alliance Among Participants Receiving Psilocybin Therapy - Alan K. Davis; Adam W. Levin; Rafael Lancelotta; Nathan D. Sepeda; Natalie Gukasyan; Sandeep M. Nayak; Frederick S. Barrett; Roland R. Griffiths (Drug and Alcohol Dependence, 2024)

Physiological Effects of Psilocybin, Psilacetin, and DOI in Rats - Shelby A. McGriff; Grant C. Glatfelter; David R. Manke; A.R. Chadeayne; Charles W. Schindler; Michaël Baumann (Drug and Alcohol Dependence, 2024)

Lifetime Depression and Psilocybin Mushroom Use in U.S. Adults, 2008-2019 - Lauren Gorfinkel; Julia M. Bujno; Claire Walsh; Dvora Shmulewitz; Deborah S. Hasin (Drug and Alcohol Dependence, 2024)

Differing Approaches to Investigating the Therapeutic Efficacy of Psilocybin Across Diverse Indications - Ryan K. Lanier; Michael P. Bogenschutz; Emmanuelle A. D. Schindler; Benjamin Kelmendi; Caitlyn Durgin; Judy Ashworth (Drug and Alcohol Dependence, 2024)

Associations Between Harm Reduction Strategy Use and Acute Psychedelic Effects in Spanish Speakers who Used LSD or Psilocybin - Rafael Lancelotta; Christopher Timmerman; Ana María Ortiz Bernal; Sandeep M. Nayak; Nathan D. Sepeda; Aki Nikolaidis; Roland R. Griffiths; Alan K. Davis (Drug and Alcohol Dependence, 2024)

Developing Core Consensus Measures for Assessment of Psilocybin Services - P. Todd Korthuis; Kim Hoffman; Adrianne R. Wilson-Poe; Jason B. Luoma; Alissa Bazinet; David Morgan; Sarann Bielavitz; Dennis McCarty; Christopher S. Stauffer (Drug and Alcohol Dependence, 2024)

Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study - Stéphanie Knatz Peck; Samantha Shao; Tessa Gruen; Kevin H. Yang; Alexandra Babakanian; Julie Trim; Daphna M. Finn; Walter H. Kaye (FOCUS The Journal of Lifelong Learning in Psychiatry, 2024)

Bridging Psilocybin-Induced Changes in the Brain’s Dynamic Functional Connectome With an Individual’s Subjective Experience - S. Parker Singleton; Amy Kuceyeski (Biological Psychiatry Cognitive Neuroscience and Neuroimaging, 2024)

Potential Differences in Psychedelic Actions Based on Biological Sex. - Shadani S; Conn K; Andrews ZB; Foldi CJ (Endocrinology, 2024)

Treating Anxiety and Depression With Psilocybin Therapy. - Amanda Paige Hanstein; Chance Felchlin (PubMed, 2024)

The Black Book of Psychotropic Dosing and Monitoring. - DeBattista C; Schatzberg AF. (2024)

Investigating the therapeutic efficacy of psilocybin in advanced cancer patients: A comprehensive review and meta-analysis. - Bader H; Farraj H; Maghnam J; Abu Omar Y. (2024)

Up-to-Date on clinical and preclinical studies of psilocybin therapy - Daisuke Ibi (Folia Pharmacologica Japonica, 2024)

Striking Long Term Beneficial Effects of Single Dose Psilocybin and Psychedelic Mushroom Extract in the SAPAP3 Rodent Model of OCD-Like Excessive Self-Grooming - Brownstien M; Lazar M; Botvinnik A; Shevakh C; Blakolmer K; Lerer L; Lifschytz T; Lerer B. (bioRxiv, 2024)

Historical Perspectives and Pharmacodynamic Actions of the Magic Mushroom (Psilocybin) for Future Global Healthcare - Bennett Lange; Luke Morgan; Christopher Mattox; Suhrud Pathak; Keyi Liu; Rishi Nadar; Jun Ren; Jeyaram Bharathi Jeyabalan; Timothy Moore; Muralikrishnan Dhanasekaran (Trends in Medical Research, 2024)

Review identifies factors associated with response to psilocybin (The Brown University Psychopharmacology Update, 2024)

The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world. - Lake S; Lucas P. (2024)

Psilocybin and 2C-B at Encoding Distort Episodic Familiarity - Manoj K. Doss; Pablo Mallaroni; Natasha L. Mason; Johannes G. Ramaekers (Biological Psychiatry Cognitive Neuroscience and Neuroimaging, 2024)

Ketamine-Induced Unresponsiveness Shows a Harmonic Shift from Global to Localised Functional Organisation - Van Maldegem M; Vohryzek J; Atasoy S; Alnagger N; Cardone P; Bonhomme V; Vanhaudenhuyse A; Demertzi A; Jaquet O; Bahri MA; Kringelbach ML; Stamatakis EA; et al. (bioRxiv, 2024)

Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A - Frederick A. Bagdasarian; Hanne D. Hansen; Jingyuan Chen; Chi-Hyeon Yoo; Michael S. Placzek; Jacob M. Hooker; Hsiao-Ying Wey (ACS Chemical Neuroscience, 2024)

Psilocybin: Medicine for My Soul. Relief from Emotional and Spiritual Pain as a Hospice Nurse Diagnosed with Cancer - Mary P. Clark (Journal of Palliative Medicine, 2024)

Assessing the Feasibility of a Custom Psychedelic-assisted Group Program on Mental and Physical Health in First Responders - Empower Research Inc (ClinicalTrials.gov, 2024)

Race and ethnicity moderate the associations between lifetime psilocybin use and past year hypertension - Grant Jones; Jocelyn A. Ricard; Matthew K. Nock (Frontiers in Psychiatry, 2024)

Effects of psilocybin on uncertain punishment learning - David S. Jacobs; Alina Bogachuk; Chloé L. Le Moing; Bita Moghaddam (Neurobiology of Learning and Memory, 2024)

Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine - Brian S. Barnett; Curtis J. Koons; Vincent Van den Eynde; Peter Kenneth Gillman; J. Alexander Bodkin (Journal of Psychoactive Drugs, 2024)

Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials - Fluyau D; Kailasam VK; Revadigar N. (medRxiv, 2024)

The cyclical revival of psychedelics in psychiatric treatment. - Appiani FJ; Caroff SN. (2024)

Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs. - Guo Q; Guo L; Wang Y; Shang S. (2024)

Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion - Johns Hopkins University (ClinicalTrials.gov, 2024)

Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study - P. Todd Korthuis; Kim Hoffman; Adrianne R. Wilson-Poe; Jason B. Luoma; Alissa Bazinet; Kellie Pertl; David L. Morgan; Ryan Cook; Sarann Bielavitz; Renae Myers; R. Cameron Wolf; Dennis McCarty; et al. (Journal of Psychopharmacology, 2024)

Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study - Imperial College London (ClinicalTrials.gov, 2024)

Licit use of illicit drugs for treating depression: the pill and the process. - Torrado Pacheco A; Moghaddam B. (2024)

A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy? - Downey AE; Bradley ER; Lerche AS; O'Donovan A; Krystal AD; Woolley J. (2024)

Comparing Cannabis Use Motivations and Dependence Across Regular Cannabis Users Who Have or Have Not Recently Used Psilocybin - Madeline Stanger; Harmony O. Soffer; Angela D. Bryan; Carillon J. Skrzynski (Cannabis and Cannabinoid Research, 2024)

Increased 5-HT2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics - Ippolito A; Vasudevan S; Hurley S; Gilmour G; Westhorpe F; Churchill G; Sharp T. (bioRxiv, 2024)

Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research. - Polito V; Liknaitzky P. (2024)

Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience - Nicholas CR; Banks MI; Lennertz RL; Wenthur CJ; Krause BM; Riedner BA; Smith RF; Hutson PR; Sauder CJ; Dunne JD; Roseman L; Raison CL. (bioRxiv, 2024)

Effects of psilocin and psilocybin on human 5-HT4 serotonin receptors in atrial preparations of transgenic mice and humans - Joachim Neumann; Kiril Dimov; Karyna Azatsian; Britt Hofmann; Ulrich Gergs (Toxicology Letters, 2024)

Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder - Sandra Szafoni; Piotr Gręblowski; Klaudia Grabowska; Gniewko Więckiewicz (Frontiers in Psychiatry, 2024)

Therapeutic Potential of Fungally Derived Psilocybin Extract in Morphine-Dependent Mice: A Research Protocol - Linda Nguyen; Sona Regonda; Adam Gaisinsky (Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal, 2024)

Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies - Petrovitch D; Mitchell SM; Van Allen J; Littlefield AK. (PsyArXiv, 2024)

A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder - University of Sydney (ClinicalTrials.gov, 2024)

Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies (PsyArXiv, 2024)

5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case study - Turkia M. (PsyArXiv, 2024)

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA - Calder A; Hasler G. (PsyArXiv, 2024)

5-MeO-DMT in the complete resolution of the consequences of chronic, severe sexual abuse in early childhood-a retrospective case study (PsyArXiv, 2024)

Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA (PsyArXiv, 2024)

The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review. - Ramos L; Vicente SG. (2024)

Study protocol for “Psilocybin in patients with fibromyalgia: brain biomarkers of action” - Julia Bornemann; James B. Close; Kirran Ahmad; Tommaso Barba; Kate Godfrey; Lauren Macdonald; David Erritzøe; David Nutt; Robin Carhart-Harris (Frontiers in Psychiatry, 2024)

The molecular structure, vibrational spectra, solvation effect, non-covalent interactions investigations of psilocin. - Holikulov U; Kazachenko AS; Issaoui N; Kazachenko AS; Raja M; Al-Dossary OM; Xiang Z. (2024)

A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity. - Wang CK; Kim G; Aleksandrova LR; Panenka WJ; Barr AM. (2024)

Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms - Ryan J. Rakoczy; Grace N. Runge; Abhishek K. Sen; Oscar Sandoval; Hunter G. Wells; Quynh Nguyen; B. Roberts; Jon H. Sciortino; William J. Gibbons; Lucas M. Friedberg; J. Andrew Jones; Matthew S. McMurray (British Journal of Pharmacology, 2024)

THU-285 Lownonpsychedelic dosed of psilocybin for the therapy of MASLD - Martina Colognesi; Daniela Gabbia; Andrea Rinaldi; Luciano Cascione; Ilaria Zanotto; Stefano Comai; Katia Sayaf; Andrea Mattarei; Marco Banzato; Gianfranco Pasut; Franco Folli; Lucia Centofanti; et al. (Journal of Hepatology, 2024)

WED-123 Female mice with cirrhosis are more prone to acute and chronic effects of psilocybin exposure without tolerance compared to male mice - Jessica L. Maltman; Derrick Zhao; Alaina M. Jaster; Yunling Tai; Jing Zeng; Javier Maeso-Gonzalez; Huiping Zhou; Jasmohan S. Bajaj (Journal of Hepatology, 2024)

Psilocybin, peyote, mescaline, and lysergic acid diethylamide (LSD) use in a nationally representative population by cancer history. - Amrit Baral; Yue Pan; Alberto J. Caban Martinez; Paulo S. Pinheiro; WayWay M. Hlaing; Denise C. Vidot (Journal of Clinical Oncology, 2024)

Therapeutic Implications of Psilocybin in the Wake of Decriminalization - Nikola Lash; George Tadros; Eman Tadros (Integrative and Complementary Therapies, 2024)

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. - Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T. (2024)

Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases - Haniff Z; Bocharova M; Mantingh T; Rucker J; Velayudhan L; Taylor D; Young A; Aarsland D; Vernon A; Thuret S. (2024)

Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply. - Aaronson ST; van der Vaart A; Sackeim HA. (2024)

Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats - Floris G; Dabrowski KR; Zanda MT; Daws SE. (bioRxiv, 2024)

Time-resolved coupling between connectome harmonics and subjective experience under the psychedelic DMT - Vohryzek J; Luppi A; Atasoy S; Deco G; Timmermann C; Carhart-Harris RL; Kringelbach ML. (bioRxiv, 2024)

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review. - Chisamore N; Johnson D; Chen MJQ; Offman H; Chen-Li D; Kaczmarek ES; Doyle Z; McIntyre RS; Rosenblat JD. (2024)

Psilocybin decreases neural responsiveness and increases functional connectivity while preserving pure-tone frequency selectivity in mouse auditory cortex - Adam T. Brockett; Nikolas A. Francis (Journal of Neurophysiology, 2024)

Therapeutic Psilocybin's Adverse Effects Mostly Resolved Within 2 Days. - Harris E (JAMA, 2024)

Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report - Harman Chopra; Timothy Furnish; Monica Verduzco-Gutierrez; David S. Jevotovsky; Joel Castellanos (Clinical Case Reports, 2024)

Medical Uses and Adverse Effects of Psilocybin - Sharmin Ghaznavi; Lourdes M Bernardez; Theodore A. Stern (The Primary Care Companion For CNS Disorders, 2024)

Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology - McGovern H; Wellman N; Hutchinson B; Oestreich LKL; Cooper SE; Fonzo G; Doss M. (PsyArXiv, 2024)

Resetting the Hippocampal Buffer: A Neurocognitive Account of Psychedelic Therapy for Anxiety-Related Psychopathology (PsyArXiv, 2024)

Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression - Aboharb F; Davoudian PA; Shao L; Liao C; Rzepka GN; Wojtasiewicz C; Indajang J; Dibbs M; Rondeau J; Sherwood AM; Kaye AP; Kwan AC. (bioRxiv, 2024)

On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders. - Hoyer D. (Authorea Preprints, 2024)

Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder. - Ehrenkranz R; Agrawal M; Penberthy JK; Yaden DB. (2024)

Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis. - Fang Q; Chan VKY; Chan SSM; Jiao Y; Wang J; Li X. (2024)

Psychedelic therapy in depression and substance use disorders. - Korkmaz ND; Cikrikcili U; Akan M; Yucesan E. (2024)

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)- and psilocybin-related death in Australia - Shane Darke; Johan Duflou; Amy Peacock; Michael Farrell; Wayne Hall; Julia Lappin (Addiction, 2024)

A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient - S Morris (Clinical Psychopharmacology and Neuroscience, 2024)

The influence of psilocybin on subconscious and conscious emotional learning - Andrea Casanova; Andres Ort; John W Smallridge; Katrin H. Preller; Erich Seifritz; Franz X. Vollenweider (iScience, 2024)

Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy - Marinis J; Clarke ST; Bedi G. (PsyArXiv, 2024)

Methodological issues undermine evidence about adverse effects of psilocybin-assisted psychotherapy (PsyArXiv, 2024)

Psilocybin increases optimistic engagement over time: computational modelling of behavior in rats - Fisher EL; Smith R; Corcoran AW; Milton LK; Conn K; Hohwy J; Foldi CJ. (bioRxiv, 2024)

Psilocybin as a new way for depression treatment - Mateusz Pawlicki; Aleksandra Kłos; Karol Stachyrak; Dawid Mika; Bartosz Mazur; Kamila Turek; Maciej Lambach; Anna Gregułą; Aleksandra Mazurek; Wiktoria Wilanowska (Journal of Education Health and Sport, 2024)

Structural characterization and comparative analysis of polymorphic forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) - Matthias Zeller; Stephan D. Parent; N. Schultheiss (Acta Crystallographica Section E Crystallographic Communications, 2024)

Alterations in brain network connectivity and subjective experience induced by psychedelics: a scoping review. - Yu Z; Burback L; Winkler O; Xu L; Dennett L; Vermetten E; Greenshaw A; Li XM; Milne M; Wang F; Cao B; Winship IR; et al. (2024)

The Classical Psychedelic Psilocybin Mitigates Oxycodone Withdrawal - M. Imad Damaj; Javier González-Maeso; Belle Buzzi (Journal of Pharmacology and Experimental Therapeutics, 2024)

Psilocybin-induced anxiolytic effects supported by transient elevation of corticosterone - N. Jones; John A. Razidlo; Zarmeen Zahid; Cody J. Wenthur (Journal of Pharmacology and Experimental Therapeutics, 2024)

Psychedelics Use and the Risk of Reduced Formal Mental Health Care - Viña S. (Research Square, 2024)

Calls to Poison Centers Involving Psilocybin Rising in Youth - Terri D’Arrigo (Psychiatric News, 2024)

Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution. - Jeffrey JK; Weintraub MJ; Grob CS. (2024)

An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients - Nova Mentis Life Science Corp (ClinicalTrials.gov, 2024)

Structural pharmacology and therapeutic potential of 5-methoxytryptamines. - Warren AL; Lankri D; Cunningham MJ; Serrano IC; Parise LF; Kruegel AC; Duggan P; Zilberg G; Capper MJ; Havel V; Russo SJ; Sames D; et al. (2024)

Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology. - Kargbo RB. (2024)

Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy - Anthony L. Back; Susanna Myers; John Guy; Juliana Pérez; Leslie Lazar Thorn; Bonnie A. McGregor (Psychedelic Medicine, 2024)